The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials

Background: Immune checkpoint inhibitors (ICIs) have made a significant breakthrough in the treatment of solid tumors; however, their use also generates unique immune-related adverse effects (irAEs). Here, we performed a systematic review and meta-analysis to assess the risk of immune-related liver...

Full description

Bibliographic Details
Main Authors: Siyao Deng, Qinyan Yang, Xiaochen Shu, Jinyi Lang, Shun Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Pharmacology
Subjects:
immune checkpoint inhibitors
PD-1/PD-L1 inhibitors
immune-related adverse events
liver dysfunction
Nivolumab
Pembrolizumab
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01063/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01063/full

Similar Items